Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: David Agus Michael Bargfrede |
| Publication date | January 4, 2015 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |